CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 854

570. Chennavasin P, Seiwell R, Brater DC, Liang WM. 1979. Pharmacodynamic analysis of
the furosemide-probenecid interaction in man. Kidney Int 16: 187-195.
571. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. 1998. Functional characteristics and
membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2,
mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 287: 800-805.
572. Chatton J, Odone M, Besseghir K, Roch-Ramel F. 1990. Renal secretion of 3 -azido-3 -
deoxythymidine by the rat. J Pharmacol Exp Ther 255: 140-145.
573. Laskin OL, de Miranda P, King DH, Page DA, Longstreth JA, Rocco L, Lietman PS.
1982. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in
humans. Antimicrob Agents Chemother 21: 804-807.
574. Inotsume N, Nishimura M, Nakano M, Fujiyama S, Sato T. 1990. The inhibitory effect
of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin
Pharmacol 30(1): 50-56.
575. Breithaupt B, Tittel M. 1982. Kinetics of allopurinol after single intravenous and
oral doses: noninteraction with benzbromarone and hydrochlorothiazide. Eur J Clin
Pharmacol 22: 77-84.
576. Colin JN, Farinotti R, Fredj G, Tod M, Clavel JP, Vignon E, Dietlin F. 1986. Kinetics
of allopurinol and oxypurinol after chronic oral administration. Interaction with

benzbromarone. Eur J Clin Pharmacol 30: 75-80.
577. Muller FO, Schall R, Groenewoud G, Hundt HKL, Merwe JC, Dyk M. 1993. The effect
of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout. Eur J Clin
Pharmacol 44: 69-72.
578. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. 2005. Involvement of uric
acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol
induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 33: 1791-1795.
579. Yamamoto T, Moriwaki Y, Takahashi Y, Suda M, Higashino K. 1991. Effects of
pyrazinamide, probenecid and benzbromarone on renal excretion of oxypurinol. Ann
Rheum Dis 50: 631-633.
580. Konig J, Seithel A, Gradhand U, Fromm MF. 2006. Pharmacogenomics of human OATP
transporters. Naunyn Schmiedebergs Arch Pharmacol 372: 432-443.
581. Niemi M, Schaffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb
R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT. 2004. High plasma pravastatin
concentrations are associated with single-nucleotide polymorphisms and haplotypes of
organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:
429-440.
582. Tirona RG, Leake BF, Merino G, Kim RB. 2001. Polymorphisms in OATP-C: iden-
tification of multiple allelic variants associated with altered transport activity among
European- and African-Americans. J Biol Chem 276: 35669-35675.
583. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu J, Sai Y, Tsuji A, Yokoi T. 2002. Genetic
polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B
(SLC21A9): allele frequencies in the Japanese population and functional analysis.
J Pharmacol Exp Ther 302: 804-813.
584. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum
M, Keppler D, Konig J. 2002. A naturally occurring mutation in the SLC21A6 gene
causing impaired membrane localization of the hepatocyte uptake trasnporter. J Biol
Chem 277: 43058-43063.